A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

PSA's February 2026 Price Hike Details PSA implemented these psa grading price increases in February 2026 to match surging ...

In an effort to slow down submissions, PSA has increased the price and turnaround times of some services levels in their system.

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Subscribe to our newsletter for the latest sci-tech ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

At the 2026 Genitourinary Cancers Symposium in San Francisco, CA, Madan discusses a study investigating short-course (3-month ...

NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...